PeptideMark

Safety Profile

Tirzepatide Side Effects: Frequency & Severity

Tirzepatide shares a similar side effect profile to semaglutide but with slightly higher rates of GI effects due to stronger incretin activity.

Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.

Black Box Warning

Risk of thyroid C-cell tumors observed in rats. Human relevance unknown. Contraindicated in patients with personal or family history of MTC or MEN 2.

Serious side effects

1

  • MTC risk

    Same rodent data as GLP-1 monotherapy; black box warning.

Common side effects

6

  • Nausea

    18-33%

    Dose-related; most intense during titration.

  • Diarrhea

    15-23%

    Usually mild to moderate.

  • Decreased appetite

    11-21%

    Expected pharmacological effect.

  • Vomiting

    8-13%

    More common at higher doses.

  • Constipation

    9-17%

    Responsive to hydration and fiber.

  • Abdominal pain

    5-10%

    Usually mild.

Uncommon side effects

2

  • Injection site reactions

    Mild erythema or pruritus.

  • Gallbladder disease

    Particularly in setting of rapid weight loss.

Rare side effects

3

  • Acute pancreatitis

    Severe abdominal pain radiating to back requires immediate evaluation.

  • Hypersensitivity reactions

    Rare angioedema and anaphylaxis reported.

  • Severe hypoglycemia

    Increased risk with insulin or sulfonylureas.

Contraindications

  • Personal or family history of MTC
  • MEN 2 syndrome
  • Hypersensitivity to tirzepatide

Drug interactions

  • Insulin and sulfonylureas — may require dose reduction
  • Oral contraceptives — reduced oral contraceptive effectiveness for 4 weeks after starting; use additional method
  • Oral medications with narrow therapeutic index

Special populations

Not studied in pregnancy. Limited elderly data. Should not be used in pediatric populations.

Overall safety summary

Tirzepatide is generally well-tolerated with GI side effects predominating. Unique to tirzepatide is a warning about reduced oral contraceptive efficacy — patients using oral contraceptives should switch to non-oral contraception or add a barrier method during the first 4 weeks.

Tirzepatide side effects: FAQ

Does tirzepatide affect birth control?

Yes — oral contraceptive effectiveness may be reduced for 4 weeks after starting tirzepatide. Use a non-oral contraceptive or add a barrier method during this period.

Back to Tirzepatide profileLegal statusResearch timeline